Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.52 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.42 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2231205 | 0.88 | CYP17A1 (0.44) | CYP17A1KCNQ4KCNQ5AAK1RXFP1 | |
| SCHEMBL15160030 | 0.88 | GAA (0.52) | CYP17A1KCNQ4KCNQ5AAK1RXFP1 | |
| SCHEMBL857284 | 0.84 | HTT (0.55) | CYP17A1KCNQ4KCNQ5GAAMAPT | |
| SCHEMBL15925258 | 0.84 | CYP17A1 (0.54) | CYP17A1KCNQ4KCNQ5RXFP1CA1 | |
| SCHEMBL3006202 | 0.84 | HPGD (0.51) | GAAMAPTMAPK1CA1CA2 | |
| SCHEMBL1322145 | 0.83 | MAPT (0.54) | CYP17A1AAK1MAPTCA1CA9 | |
| SCHEMBL2363945 | 0.83 | CYP17A1 (0.53) | CYP17A1KCNQ4KCNQ5RXFP1HTT | |
| SCHEMBL22535137 | 0.83 | MEN1 (0.51) | CYP17A1AAK1MAPTCA1CA2 | |
| SCHEMBL29834708 | 0.83 | CYP17A1 (0.53) | CYP17A1KCNQ4KCNQ5RXFP1HTT | |
| SCHEMBL19935638 | 0.83 | KCNQ4 (0.40) | CYP17A1KCNQ4KCNQ5AAK1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20250032470-A1 | Electrophilic Androgen Receptor (AR) Antagonists for AR Downregulation and Ferroptosis Induction in Cancer Cells | WAYNE STATE UNIVERSITY (US) | 2025-01-30 | — | — | US | disclosed |
| US-12133846-B2 | Electrophilic androgen receptor (AR) antagonists for AR downregulation and ferroptosis induction in cancer cells | WAYNE STATE UNIVERSITY (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240308971-A1 | ALLOSTERIC INHIBITOR OF WEE1 KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2024-09-19 | — | — | US | disclosed |
| CN-117800946-A | Urea compound, pharmaceutical composition and application thereof | 中国药科大学 | 2024-04-02 | — | — | CN | disclosed |
| CN-117304180-A | Heterocyclic compound, pharmaceutical composition containing heterocyclic compound, and preparation method and application of heterocyclic compound | 百极弘烨(南通)医药科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-3412670-B1 | PYRIDINE DERIVATIVES INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USE THEREOF | SAMJIN PHARM CO LTD (KR) | 2022-03-09 | — | — | EP | disclosed |
| US-20210309630-A1 | ALLOSTERIC INHIBITOR OF WEE1 KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-10-07 | — | — | US | disclosed |
| US-20200129458-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2020-04-30 | — | — | US | disclosed |
| US-20030105324-A1 | Camptothecin analogs and methods of preparation thereof | CURRAN DENNIS P (US) | 2003-06-05 | — | — | US | disclosed |
| US-20020193598-A1 | Camptothecin analogs and methods of preparation thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-19 | — | — | US | disclosed |
| EP-1017399-A4 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIV PITTSBURGH (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6455699-B1 | SUCH AS (20S)10-HYDROXY-7-TERT-BUTYLDIMETHYLSILYL-CAMPHTOTHECIN; ANTITUMOR AGENTS; SOLUBILITY; BIOAVAILABILITY/ BIODISTRIBUTION | UNIVERSITY OF PITTSBURGH | 2002-09-24 | — | — | US | disclosed |
| EP-1140948-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIVERSITY OF PITTSBURGH (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6150343-A | 10-HYDROXY-7-SUBSTITUTED SILYLCAMPTOTHECIN DERIVATIVE IS USED AS ANTICARCINOGENIC AND ANTITUMOR AGENT | UNIVERSITY OF PITTSBURGH (US) | 2000-11-21 | — | — | US | disclosed |
| US-6136978-A | CYCLIZING SILYL COMPOUND WITH ARYL ISONITRILE COMPOUND TO FORM SILYL CAMPTOTHECIN DERIVATIVE | UNIVERSITY OF PITTSBURGH (US) | 2000-10-24 | — | — | US | disclosed |
| EP-1017399-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | University of Pittsburgh (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-2000035924-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIVERSITY OF PITTSBURGH (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999009996-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIVERSITY OF PITTSBURGH (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129458-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | GLP1R, GPR119, GIPR | CYP17A1 418/4885KCNQ4 3112/4885KCNQ5 3324/4885 |
| US-20210309630-A1 | ALLOSTERIC INHIBITOR OF WEE1 KINASE | WEE1, WEE2, PAXBP1 | CYP17A1 2782/4885KCNQ4 4167/4885KCNQ5 4118/4885 |
| US-20240308971-A1 | ALLOSTERIC INHIBITOR OF WEE1 KINASE | WEE1, WEE2, PPME1 | CYP17A1 2283/4885KCNQ4 4222/4885KCNQ5 3947/4885 |
| US-20020193598-A1 | Camptothecin analogs and methods of preparation thereof | TOP1, TOP2A, TOP2B | CYP17A1 359/4885KCNQ4 4732/4885KCNQ5 4733/4885 |
| US-12133846-B2 | Electrophilic androgen receptor (AR) antagonists for AR downregulation and ferroptosis induction in cancer cells | AR, GSR, GPX1 | CYP17A1 254/4885KCNQ4 4141/4885KCNQ5 4390/4885 |
| US-20030105324-A1 | Camptothecin analogs and methods of preparation thereof | HCCS, ADCY10, TOP2A | CYP17A1 582/4885KCNQ4 4157/4885KCNQ5 4084/4885 |
| US-20250032470-A1 | Electrophilic Androgen Receptor (AR) Antagonists for AR Downregulation and Ferroptosis Induction in Cancer Cells | AR, GSR, GPX1 | CYP17A1 254/4885KCNQ4 4141/4885KCNQ5 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.